PDO Screen – Patient-derived Organoids meet Cancer Modeling
Discover how patient-derived organoids can revolutionize oncology research by enabling accurate modeling of tumor biology and predicting patient response to treatment.
HUB's blog
The FDA Modernization Act 2.0: A patient-centric paradigm shift in drug development
Explore what the new legislative bill means for the future of ...
Challenges in preclinical modeling of cancer immunity
Learn how to select the right model for your immunotherapy ...
Do you need a license to work with HUB Organoid® Technology?
Explore HUB’s license offerings and how they apply to your organoid ...
Forecasting a champion: How HUB Organoids® can speed up the drug development timeline to about five years
Learn why you should invest in patient-derived HUB Organoids® for ...
Ask the experts - organoids as model systems
In this last episode of our "Ask the experts" series we explore the ...
Ask the experts - organoids in drug development
After discussing HUB Organoids™ applications to viral and oncology ...
Ask the experts - organoids for oncology studies
In the first post from our "Ask the experts" series we have answered ...
Ask the experts - organoids for viral infection studies
HUB and STEMCELL Technologies experts gathered virtually for a ...